Core Viewpoint - The company, 基石药业-B (02616.HK), will hold a board meeting on March 26, 2026, to consider and approve its annual performance for the year ending December 31, 2025, and will provide a business update thereafter [1] Group 1: Upcoming Events - The board meeting is scheduled for March 26, 2026, to discuss the annual performance and related approvals [1] - A voluntary business update announcement will be released after the board meeting on the same day [1] - An investor conference call is planned for March 27, 2026, to discuss the business update [1] Group 2: Key Updates to be Discussed - Updates on CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) including Phase I clinical data, Phase II trial progress, and business development dynamics [1] - Latest progress on CS5001 (ROR1 ADC) clinical trials [1] - Global commercialization progress of舒格利单抗 (anti-PD-L1 antibody) [1] - Sales performance of 普吉华® (普atinib) after its inclusion in China's national medical insurance directory effective January 1, 2026 [1] - Research and development progress on preclinical pipeline and plans for IND submissions in 2026 [1]